Pemetrexed Market
Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name Alimta. In 2004, Alimta (Pemetrexed injection) was approved by US FDA (Food and Drug Administration) in combination with cisplatin as an initial treatment for patients with malignant pleural mesothelioma. As a single agent for the maintenance treatment of patients with locally advanced or metastatic non squamous (non-small cell lung cancer) NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. It is a single agent for the treatment of patients with recurrent, metastatic non-squamous (non-small cell lung cancer) NSCLC after prior chemotherapy.
Market Dynamics
Launch of generic version of pemetrexed in key region is expected to increase affordability of pemetrexed, which in turn is expected to drive global pemetrexed market growth over the forecast period. For instance, in July 2018, STADAPHARM GmbH, an international pharmaceutical company the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe. The drug is used for treating locally advanced, metastasized and non-small cell lung cancer and is a generic of the product Alimta by Lilly. The launch helped the company in further expansion in pharmaceutical sector.
High prevalence of non-small cell lung cancer and pleural mesothelioma is expected to rise the demand for pemetrexed drive global pemetrexed market growth over the forecast period. For instance, according to the data published by American Society of Clinical Oncology, an oncology organization, in January 2018, in the U.S. around 234,030 adults (121,680 men and 112,350 women) were diagnosed with lung cancer among which non-small cell lung cancer is the most common type of lung cancer, accounting for 80% to 85% of all lung cancer diagnose.
Furthermore, key players in the market are dedicated to expand the indication of its pemetrexed drugs in order to increase its sale and generate high revenues. For instance, in June 2018, Eli Lilly and Company, a U.S.-based pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for a new indication for ALIMTA (pemetrexed for injection) in combination with carboplatin and KEYTRUDA (pembrolizumab) for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 25 market data tables and 20 figures on “Global Pemetrexed Market” - forecast to 2030
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWe help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients